News | February 24, 2026
AIM ImmunoTech advances Phase 2 pancreatic cancer trial with Ampligen and Imfinzi
The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands
The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
200+ HR leaders and CXOs convened to discuss workforce health, preventive care, and organisational wellbeing as strategic business priorities
BLA is based on a robust data package supporting similarity to Orencia (abatacept) IV for infusion through totality of evidence including pharmacokinetic (PK) data
The clinical program has benefited from extensive European Union support, including the IMI2 TRIC-TB and UNITE4TB projects, as well as funding from the EDCTP2 bEto-TB project
Both non-transfusion-dependent and transfusion dependent cohorts met their respective primary and secondary endpoints
The drug’s safety profile in LIBRETTO-432 aligned with previous selpercatinib studies, showing no unexpected concerns
If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations
The agreement ensures BIOEMTECH customers can consistently obtain Ac-225 for preclinical studies
This approval builds on the recent transformation RYBREVANT FASPRO brought to lung cancer care
Subscribe To Our Newsletter & Stay Updated
